Sepracor Inc.

Sepracor Inc.

Sepracor Inc. company focuses its drug development efforts in two main therapeutic categories: respiratory and central nervous system (CNS) disorders. Its marketed products include asthma drug Xopenex, insomnia therapy Lunesta, and chronic obstructive pulmonary disease (COPD) treatment Brovana. Sepracor markets its products to primary care physicians and some specialists in the US; it also has some limited operations in Canada. It has licensed international development and commercialization rights for Lunesta to Eisai and GlaxoSmithKline. Sepracor was acquired for $2.6 billion by Japanese firm Dainippon Sumitomo Pharma in 2009.

Contact Details

Office Address

Sepracor Inc.
84 Waterford Drive
Marlborough, MA, USA 01752
Phone: (508) 481-6700
Fax: (508) 357-7499

Executives

Chairman

Timothy J. Barberich

President, CEO, and Director

Adrian Adams

Business Reviews for Sepracor Inc.

Related Companies